MilliporeSigma increasing capacity, speed to market

By The Science Advisory Board staff writers

October 28, 2021 -- MilliporeSigma has launched new technology to support efforts to double its antibody drug conjugate (ADC) and high-potent active pharmaceutical ingredient (HPAPI) capacity.

The company launched ChetoSensar to address the hydrophobicity of ADCs, the company said. Many ADC candidates have poor aqueous solubility; MilliporeSigma estimates that more than 20% of ADC clinical terminations are caused by this issue. ChetoSensar technology improves ADC solubility, the company said.

Millipore has also launched a new platform called Dolcore, which can increase the speed to market for dolostatin-based ADC payloads by up to a year, the company said.

In addition, the company will enhance the ADC capabilities of its clinical manufacturing facility in St. Louis, Missouri, in December. Last year, the company announced a $65 million expansion of its facility near Madison, WI, which it expects will double its HPAPI kilo lab capacity and enable the company to expedite the manufacture of HPAPIs, ADC linker/payloads, and complex APIs.

MilliporeSigma, the U.S. and Canadian life science business of Merck, has launched new technology and expanded its capacity to advance ADC therapies.
MilliporeSigma, the U.S. and Canadian life science business of Merck, has launched new technology and expanded its capacity to advance ADC therapies. Image courtesy of MilliporeSigma.
MilliporeSigma doubles viral vector production with new facility
MilliporeSigma has opened a second contract development manufacturing facility in California to focus on viral vector technologies for cell and gene therapy.
MilliporeSigma scales up lipid production for COVID-19 vaccines
MilliporeSigma announced that it has launched a new high-purity synthetic cholesterol product to meet demand for lipids, a component of messenger RNA-based...
MilliporeSigma boosts capacity at French assembly facility
MilliporeSigma is adding a single-use assembly production unit to its facility in Molsheim, France.
MilliporeSigma acquires AmpTec
MilliporeSigma has purchased messenger RNA firm AmpTec. The deal is expected to boost MilliporeSigma's ability to develop and manufacture messenger RNA...
MilliporeSigma invests $47M in U.S. biomanufacturing facilities
MilliporeSigma is increasing its manufacturing footprint in the U.S. with a $47 million investment in its Danvers, MA, and Jaffrey, NH, biomanufacturing...

Copyright © 2021 scienceboard.net


Conferences
Microscopy and Microanalysis Meeting
July 31 - August 4
Portland, Oregon United States
Glasgow International Health Festival
August 24-27
Glasgow, Glasgow City United Kingdom
Pharma Competitive Intelligence Conference and Exhibition
September 21-22
Newark, New Jersey United States
BioProcess International (BPI) Conference
September 27-30
Boston, Massachusetts United States
Connect
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter